Complement activation by PEGylated single-walled carbon nanotubes is independent of C1q and alternative pathway turnover

Molecular Immunology

Volumn 45, Issue 14, 2008, Pages 3797-3803

  Hamad, Islam ^a   Christy Hunter, A ^a   Rutt, Kenneth J ^a   Liu, Zhuang ^b   Dai, Hongjie ^b   Moein Moghimi, S ^c  

^a UNIVERSITY OF BRIGHTON   (United Kingdom)

^b STANFORD UNIVERSITY   (United States)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Biomaterials; C4; Carbon nanotubes; Complement system; Drug delivery system; Nanomedicine; SC5b 9

Indexed keywords

AMINOPOLY(ETHYLENE GLYCOL)5000 DISTEAROYLPHOSPHATIDYLETHANOLAMINE; COMPLEMENT COMPONENT C1Q; MONOCLONAL ANTIBODY; N ACETYLGLUCOSAMINE; PHOSPHATIDYLETHANOLAMINE; SINGLE WALLED NANOTUBE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; COMPLEMENT ACTIVATION; ENZYME INHIBITION; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN METABOLISM; RAT;

ADULT; CARBON; COMPLEMENT ACTIVATION; COMPLEMENT C1Q; COMPLEMENT C3-C5 CONVERTASES; COMPLEMENT C4; COMPLEMENT PATHWAY, ALTERNATIVE; HUMANS; MALE; NANOTUBES; POLYETHYLENE GLYCOLS;

RATTUS;

EID: 48049083322     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2008.05.020     Document Type: Article

References (27)

1. Andersson J., Ekdahl K.N., Larsson R., Nilsson U.R., and Nilsson B. C3 adsorbed to a polymer surface can form an initiating alternative pathway convertase. J. Immunol. 168 (2002) 5786-5791
2. Chanan-Khan A., Szebeni J., Savay S., Liebes L., Rafique N.M., Alving C.R., and Muggia F. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann. Oncol. 14 (2003) 1430-1437
3. Cherukuri P., Gannon C.J., Leeuw T.K., Schmidt H.K., Smalley R.E., Curley S.A., and Weisman B. Mammalian pharmacokinetics of carbon nanotubes using intrinsic near-infrared fluorescence. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 18882-18886
4. Dos Santos N., Allen C., Doppen A.M., Cox K.A.K., Gallegher R.C., Karlsson G., Edwards K., Kenner G., Samuells L., Webb M.S., and Bally M.B. Influence of poly(ethylene glycol) grafting density and polymer length on liposomes: relating plasma circulation lifetimes to protein binding. Biochim. Biophys. Acta-Biomembr. 1768 (2007) 1367-1377
5. Fujita T. Evolution of lectin-complement pathway and its role in innate immunity. Nat. Rev. Immunol. 2 (2002) 346-353
6. Gbadamosi J.K., Hunter A.C., and Moghimi S.M. PEGylation of microspheres generates a heterogeneous population of particles with differential surface characteristics and biological performance. FEBS Lett. 532 (2002) 338-344
7. Hamad I., and Moghimi S.M. Critical issues in site-specific targeting of solid tumours: the carrier, the tumour barriers and the bioavailable drug. Exp. Opin. Drug Deliv. 5 (2008) 205-219
8. Hattori R., Hamilton K.K., McEver R.P., and Sims P.J. Complement proteins C5b-9 induce secretion of high molecular-weight multimers of endothelial von Willebrand-factor and translocation of granule membrane-protein GMP-140 to the cell-surface. J. Biol. Chem. 264 (1989) 9053-9060
9. Krarup A., Thiel S., Hansen A., Fujita T., and Jensenius J.C. L-ficolin is a pattern recognition molecule specific for acetyl groups. J. Biol. Chem. 279 (2004) 47513-47519
10. Lambris J.D., Ricklin D., and Geisbrecht B.V. Complement evasion by human pathogens. Nat. Rev. Microbiol. 6 (2008) 132-142
11. Liu Z., Cai W., He L., Nakayama N., Chen K., Sun X., Chen X., and Dai H. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat. Nanotechnol. 2 (2007) 47-52
12. Liu Z., Davis C., Cai W., He L., Chen X., and Dai H. Circulation and long-term fate of functionalized, biocompatible single-walled carbon nanotubes in mice probed by Raman spectroscopy. Proc. Natl. Acad. Sci. U.S.A. 105 (2008) 1410-1415
13. Matsushita M., Endo Y., and Fujita T. Complement-activating complex of ficolin and mannose-binding lectin-associated serine protease. J. Immunol. 164 (2000) 2281-2284
14. Moghimi S.M. Chemical camouflage of nanospheres with a poorly reactive surface: towards development of stealth and target-specific nanocarriers. Biochim. Biophys. Acta-Mol. Cell Res. 1590 (2002) 131-139
15. Moghimi S.M., and Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res. 42 (2003) 463-478
16. Moghimi S.M., Hunter A.C., and Murray J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 53 (2001) 283-318
17. Moghimi S.M., Hamad I., Andresen T.L., Jørgensen K., and Szebeni J. Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production. FASEB J. 20 (2006) E2057-E2067
18. Pfeifer P.H., Kawahara M.S., and Hugli T.E. Possible mechanism for in vitro complement activation in blood and plasma samples: Futhan/EDTA controls in vitro complement activation. Clin. Chem. 45 (1999) 1190-1199
19. Salvador-Morales C., Flahaut E., Sim E., Sloan J., Green M.L.H., and Sim R.B. Complement activation and protein adsorption by carbon nanotubes. Mol. Immunol. 43 (2006) 193-201
20. Szebeni J. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology 216 (2005) 106-121
21. Szebeni J., Wassef N.M., Spielberg H., Rudolph A.S., and Alving C.R. Complement activation in rats by liposomes and liposome-encapsulated hemoglobin: evidence for anti-lipid antibodies and alternative pathway activation. Biochem. Biophys. Res. Commun. 205 (1994) 255-263
22. Szebeni J., Wassef N.M., Rudolph A.S., and Alving C.R. Complement activation in human serum by liposome-encapsulated hemoglobin: the role of natural anti-phospholipid antibodies. Biochim. Biophys. Acta-Biomembr. 1285 (1996) 127-130
23. Szebeni J., Wassef N.M., Hartman K.R., Rudolph A.S., and Alving C.R. Complement activation in vitro by the red cell substitute, liposome-encapsulated hemoglobin: mechanism of activation and inhibition by soluble complement receptor type 1. Transfusion 37 (1997) 150-159
24. Szebeni J., Muggia F.M., and Alving C.R. Complement activation by cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J. Natl. Cancer Inst. 90 (1998) 300-306
25. Szebeni J., Baranji L., Sávay S., Bodó M., Milosevits J., Alving C.R., and Bünger R. Complement activation-related cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart function. Am. J. Physiol. Heart Circ. Physiol. 290 (2006) H1050-1058
26. Toda M., Kitazawa T., Hirata I., Hirano Y., and Iwata H. Complement activation on surfaces carrying amino groups. Biomaterials 29 (2008) 407-417
27. Vorup-Jensen T., Petersen S.V., Hansen A.G., Poulsen K., Schwaeble W., Sim R.B., Reid K.B., Davis S.J., Thiel S., and Jensenius J.C. Distinct pathways of mannan-binding lectin (MBL)- and C1-complex autoactivation revealed by reconstitution of MBL with recombinant MBL-associated serine protease-2. J. Immunol. 165 (2000) 2093-2100